Study of the Use of Low Level Laser Therapy to Reduce Acne
The purpose of this study is to determine whether low level laser light therapy is effective in the treatment of acne blemishes.
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Pilot Study to Evaluate the Efficacy of Low-level Laser Therapy in Reducing Blemishes by Quantifying a Decreasein Signs of Blemishes, Both Non-inflammatory and Inflammatory|
- Grade on the Burton et al. Acne Severity Grade scale [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- number of inflammatory lesions [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
- number of non-inflammatory lesions [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||March 2010|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
Device: Erchonia EML
Acne is a chronic inflammatory disorder plaguing the sebaceous follicle, and debate still remains over what truly initiates lesion formation. Experts agree that an increase in androgen production plays a significant role in the onset of acne. Androgens promote the increase in size of sebaceous glands and stimulate sebum production. The simple act of sebaceous gland stimulation via androgens could ultimately promote the upregulation of pro-inflammatory cytokines like TNF-α and IL-1α without propionibacteria even being present. The synthesis of IL-α and other pro-inflammatory cytokines including prostaglandins occurs via the inducible enzyme known as cyclooxygenase-2 (COX-2). Studies analyzing the pathogenesis of mucositis have identified COX-2 as an important contributor to the upregulation of pro-inflammatory cytokines and thus a major contributor to the progression of the disorder itself.
Recent evidence indicates that low-level laser therapy (LLLT) is able to significantly diminish the expression of COX-2, resulting in the reduction of inflammation. The ability to modulate the COX-2 pathways via LLLT is believed to inhibit the production of pro-inflammatory cytokines (i.e. TNF-α and IL- α) present in acne-prone skin.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01276535
|United States, Texas|
|Austin, Texas, United States, 78746|